Navigation Links
New Details Presented at the World Parkinson Congress on Neurologix's Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
Date:10/1/2010

y affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information about factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2009 Annual Report on Form 10-K. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.

    Contacts:
    Neurologix
    Marc Panoff, 201-592-6451
    Chief Financial Officer
    marcpanoff@neurologix.net

    Cohn & Wolfe
    Jennifer Paganelli, 212-798-9847
    Jennifer.Paganelli@cohnwolfe.com




    '/>"/>
    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
    2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
    3. Newly Published Article Details How PGS Techniques Directly Effect Successful Pregnancy Outcomes
    4. Kendle Announces Details Regarding Third Quarter 2009 Earnings Conference Call and Webcast
    5. Young Innovations, Inc. Provides Third Quarter Conference Call Details
    6. Cord Blood America Details Las Vegas Laboratory Progress in Analyst Interview
    7. Young Innovations, Inc. Provides 4th Quarter Conference Call Details
    8. Kendle Announces Details Regarding Second Quarter 2010 Earnings Conference Call and Webcast
    9. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
    10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
    11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/20/2014)... Colo. , Oct. 20, 2014  Luoxis ... (NYSE MKT: AMPE), today announced that its academic ... clinical and research potential for its novel RedoxSYS ... potential (ORP) in the body in response to ... value of ORP as a clinical marker will ...
    (Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
    (Date:10/20/2014)... , Oct. 20, 2014  AnaptysBio, Inc., a ... antibodies, today announced the appointment of Marco ... Londei will lead the preclinical and clinical development ... "We are pleased to welcome Dr. Londei to ... , President and Chief Executive Officer of AnaptysBio. ...
    Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
    ... Oct. 28, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... Paul Bisaro, Watson,s President and Chief Executive Officer, will provide ... 2011 Annual Credit Suisse Health Care Conference on Wednesday, November ... the Arizona Biltmore Hotel in Phoenix. The presentation will be ...
    ... Pharma, LLC. is pleased to announce today the presentation ... and completed analysis of a Phase I study of ... stabilized analogue of endomorphin 1, a naturally occurring pain ... in normal healthy volunteers with additional pharmacodynamic end points.  ...
    Cached Medicine Technology:
    (Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
    (Date:10/22/2014)... 2014 Although there are only 24 hours in ... people who have trouble finding time within their busy schedules for ... long periods of time to get in shape. Here are five ... the go. , Change Up Your Commute , Consider riding ... add some exercise into your daily routine. If you must use ...
    (Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
    (Date:10/22/2014)... (HealthDay News) -- Two sisters in high school have ... Ilina and Medha Krishen use electronic stethoscopes, which electronically ... in breathing patterns or heartbeats. Ilina, a senior ... to find a way to detect early lung damage ... electronic stethoscope, Ilina recorded one breath cycle each from ...
    (Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
    Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
    ... are less prevalent than thought. However, when they do ... characteristics measured as early as five months, according to a ... SLEEP. , The study, led by Valrie Simard, under the ... sampled 987 children in the Province of Quebec, who were ...
    ... Forest University Baptist Medical Center suggests that a three-drug ... glioblastoma multiforme (GBM), a type of brain tumor with ... been developed, and the team is working on the ... cells and spare healthy brain., Waldemar Debinski, M.D., Ph.D., ...
    ... ... Boards Merge, CANTON, Ohio, Dec. 31 Two county boards have,merged ... Alcohol and Drug Addiction Services Board of Stark County are,now a single ... "The combined Board will create a stronger advocate for people with,mental ...
    ... YORK, Dec. 31 The holidays are here, which ... drinks like gingerbread,cookies and egg nog! But overindulging in ... on the pounds, it can also take a toll ... from Pharmavite at:, http://media.medialink.com/WebNR.aspx?story=34272 , Registered journalists can ...
    ... 31 SPX Corporation,(NYSE: SPW ) today ... a,global manufacturer of process equipment and engineered solutions ... APV greatly enhances our process equipment,operations serving key ... Pacific," said Chris Kearney, Chairman, President and CEO ...
    ... May Be Cost-Effective Method of Screening for Breast Cancer, but ... A cost-effectiveness study of the value of digital mammography breast ... result in sufficient health gains to warrant its increased cost ... women with dense breasts (Article, p. 1). , The study ...
    Cached Medicine News:Health News:Preschoolers' nightmares less prevalent, are trait-like and associated with personality 2Health News:Preschoolers' nightmares less prevalent, are trait-like and associated with personality 3Health News:Research suggests new treatment suitable for all patients 2Health News:Research suggests new treatment suitable for all patients 3Health News:Combined Boards Provide Better Care to More Clients More Efficiently 2Health News:SPX Corporation Completes Acquisition of APV 2Health News:Annals of Internal Medicine tip sheet for Jan. 1, 2008, issue 2
    8 X 1 Red Filter. Color Filters are designed to filter out all other color regions of the visible spectrum except the specified color. Color Filters are excellent for contrast enhancement and color r...
    Last 3-6 months average refrigeration will prolong life. Pupil gauge printed on penlight 4 1/2" long 1/2" around....
    Doctors six-pack long lasting, disposable, diagnostic penlights. Constant use time of 30 minutes. One year shelf life warranty from date of purchase. Convenient clip-activated switch & imprinted medi...
    Heavy duty, all purpose illuminator available in black only. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentrated l...
    Medicine Products: